FDA Approves Liver Iron Scanner for Deferasirox as Class II Tool
Published Date: 8/21/2025
Rule
Summary
The FDA is officially classifying a special imaging device that helps doctors measure liver iron levels for patients using deferasirox as a Class II device with safety rules. This change means the device will be safer and easier to get, helping patients get better care faster. Medical device makers and patients can expect smoother approvals without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Imaging Test for Deferasirox Becomes Safer
If you are a patient who needs an imaging test to measure liver iron while using deferasirox, the FDA has classified the liver iron concentration imaging companion diagnostic for deferasirox as a Class II device with special controls. The FDA says this classification provides a reasonable assurance of safety and effectiveness and will help enhance patient access by reducing regulatory burdens, which can make the device safer and easier to get.
Easier Approvals for Device Makers
If you make medical devices, the FDA's classification of the liver iron concentration imaging companion diagnostic for deferasirox into Class II with special controls is intended to reduce regulatory burdens. The rule says this will enhance access and may lead to smoother approvals without extra costs or delays for device makers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in